CN113238060A - Kit for predicting or diagnosing myocarditis - Google Patents
Kit for predicting or diagnosing myocarditis Download PDFInfo
- Publication number
- CN113238060A CN113238060A CN202110500253.5A CN202110500253A CN113238060A CN 113238060 A CN113238060 A CN 113238060A CN 202110500253 A CN202110500253 A CN 202110500253A CN 113238060 A CN113238060 A CN 113238060A
- Authority
- CN
- China
- Prior art keywords
- kit
- gdf15
- reagent
- myocarditis
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to application of a reagent for detecting the concentration level of GDF15 in serum or plasma in preparing a preparation for predicting or diagnosing the risk of myocarditis of an individual to be detected. The invention also relates to a kit for predicting or diagnosing myocarditis, which detects the concentration of a protein that is GDF15 or GDF15 and troponin I in a subject. The invention also provides a kit for predicting or diagnosing myocarditis, which has high sensitivity, good stability, wide linear range and strong anti-interference capability and can be widely used for clinical auxiliary diagnosis of myocarditis.
Description
Technical Field
The invention belongs to the technical field of clinical diagnostics, and particularly relates to a kit for predicting or diagnosing myocarditis, wherein the kit is used for determining the level of GDF15 to predict or diagnose myocarditis diseases.
Background
Myocarditis refers to a disease in which localized or diffuse inflammatory lesions of the myocardium are the main manifestation, and according to established Dallas criteria, the histological evidence of intramyocardial infiltration is myocardial inflammatory cell infiltration accompanied by adjacent myocardial cell degeneration and necrosis. Myocarditis is often caused by a common viral infection or by an immune response following a viral infection, and causes include both infectious and non-infectious groups. Infectious agents include bacteria, fungi, protozoa, parasites, spirochetes, rickettsiae and viruses. Non-infectious factors have the following aspects: (1) immune-mediated diseases (allergens, alloantigens, autoantigens); (2) toxicity (drugs, heavy metals, biologically toxic substances, physical injury, etc.). The most common cause is viral infection, with other factors being rare.
Myocarditis is clinically manifested differently, mainly depending on the wide extent and severity of the pathological changes, but few of them are completely asymptomatic, mild ones are manifested as nonspecific symptoms such as fever, cough, diarrhea, etc., and severe ones are manifested as severe arrhythmia, heart failure, cardiogenic shock and even death. Thus, the likelihood of relying solely on clinical symptoms to diagnose myocarditis is low.
For this purpose, some biological markers are used for auxiliary examination. Currently, the clinical auxiliary examination markers are mainly troponin I, troponin T or creatine kinase isozyme. However, cardiac troponin is a highly specific diagnostic marker for myocardial tissue damage (e.g., myocardial infarction), and the specificity for myocarditis remains to be studied. Therefore, more myocarditis markers are sought.
Growth differentiation factor-15 (Growth/differentiation factor 15, GDF15) is a member of the transforming Growth factor-beta superfamily (TGF beta super family). Currently, diagnostic markers of GDF15 are mainly focused on the assessment of the condition of heart failure and the prognosis of diseases such as myocardial infarction and cerebral infarction, for example, US20100167331a1 discloses the diagnosis of whether Percutaneous Cardiac Intervention (PCI) is successful in a subject with stable coronary heart disease by detecting GDF 15; US7955854B2 discloses diagnosing whether a subject exhibiting atrial fibrillation is heart failure by detecting GDF 15; predicting risk of renal failure in cardiac surgery patients by detecting GDF15 is disclosed in CN 102652261B; CN106257287B discloses a new application of growth differentiation factor 15 in the evaluation of the first stroke of hypertensive patients.
In addition, before and after 2017, the medical community also finds the potential of GDF15 in obesity treatment, and the pharmaceutical huge number of three drugs, namely Li Lai, Novonide and Qiangsheng, simultaneously report that GDF15 can lose weight through GFRAL of a receptor thereof in Nature Medicine. However, the use of GDF15 for the prediction and/or diagnosis of myocarditis is not known in the art.
Disclosure of Invention
In order to solve the above problems, the present invention provides, in a first aspect, a use of an agent for detecting a GDF15 concentration level in serum or plasma for preparing a preparation for predicting or diagnosing a risk of myocarditis in an individual to be tested. When the concentration of GDF15 in the serum or plasma of the subject is increased, the risk of myocarditis of the subject is also increased.
In another aspect of the invention, a kit for predicting or diagnosing myocarditis is provided, which is for detecting the concentration level of GDF15 in serum or plasma.
In addition, the applicant also unexpectedly found that although the concentrations of GDF15 and troponin I in myocarditis patients are generally higher than those of healthy people, the numerical trends of GDF15 and troponin I in different myocarditis patients are inconsistent, and therefore, when GDF15 and troponin I are simultaneously detected, the accuracy of predicting or diagnosing myocarditis can be improved. Namely, the kit for predicting or diagnosing myocarditis provided by the invention is used for simultaneously treating the protein concentration of GDF15 and the concentration of troponin I in serum or plasma.
Further, the kit for predicting or diagnosing myocarditis of the present invention comprises:
a GDF15 first antibody conjugated to a solid support; a GDF15 second antibody labeled with a detectable label;
the first and second antibodies each specifically bind to a different epitope of GDF 15.
In the present invention, the "solid phase carrier" may be a solid phase carrier in the form of beads (beads), microwell plates, test tubes, rods, membranes (membranes), test pieces, or the like, which are made of a material such as polystyrene, polycarbonate, polyvinyltoluene, polypropylene, polyethylene, polyvinyl chloride, nylon, polymethacrylate, polyacrylamide, latex, liposome, gelatin, agarose, cellulose, glass, metal, ceramic, or magnetic material. Preferably, the solid phase carriers are magnetic particles, more preferably, the solid phase carriers are magnetic particles.
In the present invention, a "detectable label" refers to a substance that can be detected spectroscopically, photochemically, biochemically, immunochemically, electrically, optically, or chemically, for example, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, β -galactosidase, and other enzymes commonly used in ELISA), fluorescent dyes (e.g., fluorescein, Texas Red, rhodamine, and green fluorescent protein, etc., see, for example, Molecular Probes, Eugene, Oreg., USA), radioactive labels (e.g., 3H, 125I, 35S, 14C, or 32P), luminescent substances (e.g., chemiluminescent substances, further, such as acridine (e-9-carboxamide), phenanthridine (phenothridine), dioxetane (dioxiranes), and luminol, etc.).
Preferably, the "detectable label" is a chemiluminescent substance. "chemiluminescent substance" refers to a substance that forms an excited intermediate by catalysis by a catalyst and/or oxidation by an oxidant, and that emits photons when the excited intermediate returns to a stable ground state.
Preferably, the "detectable label" is an "acridinium chemiluminescent substance". "acridine chemiluminescent substance" refers to acridinium esters and derivatives thereof, acridinium sulfonamide chemiluminescent substances, and lucigenins, which are suitable for use in chemiluminescent immunoassay systems. In alkaline H2O2 solution, when molecules are attacked by hydrogen peroxide ions, unstable dioxyethane is generated, and the dioxyethane is decomposed into CO2 and electron excited N-methylacridone, and photons are emitted when the dioxyethane returns to the ground state.
Preferably, the "detectable label" is an "acridinium ester derivative". "acridinium ester derivatives" are well known in the field of chemiluminescence immunoassay, and for example, chinese patent 201510090045.7 describes acridinium ester derivatives for chemiluminescence immunoassay and a preparation method thereof; law et al (Novel poly-subsampled aryl acrylate esters and the use in immunoassays, J Biolumin Chemiln.1989 Jul; 4(1):88-98) synthesized a series of acridinium ester analogs that could be used in immunoassays.
Further, the kit for predicting or diagnosing myocarditis of the present invention comprises: reagent 1 and reagent 2. Wherein, the reagent 1 comprises: buffer, inorganic salt ions, stabilizers, surfactants, preservatives, gluconic acid, and a first antibody to magnetic microparticle coated GDF 15; the reagent 2 comprises: buffers, inorganic salt ions, stabilizers, surfactants, preservatives, and a second antibody to acridinium ester labeled GDF 15.
Further, the kit for predicting or diagnosing myocarditis of the present invention comprises: reagent 1 and reagent 2. Wherein, the reagent 1 comprises: 10-200 mmol/L of buffer solution, 150-600 mmol/L of inorganic salt ions, 10-50 g/L of stabilizing agent, 0.1-1.0 mL/L of surfactant, 0.1-0.6 mL/L of preservative, 2-5 g/L of gluconic acid and 0.2-0.8 ug/mL of first antibody of GDF15 coated by magnetic particles; the reagent 2 comprises: 10-200 mmol/L of buffer solution, 150-600 mmol/L of inorganic salt ions, 10-20 g/L of stabilizing agent, 0.1-1.0 mL/L of surfactant, 0.1-0.6 mL/L of preservative and 0.05-0.4 ug/L of second antibody of acridine ester labeled GDF 15.
Further, the kit for predicting or diagnosing myocarditis of the present invention comprises: reagent 1 and reagent 2. Wherein, the reagent 1 comprises: 0.5ug/mL of first antibody of GDF15 coated by magnetic particles, 2.56g/L of disodium hydrogen phosphate, 0.436g/L of sodium dihydrogen phosphate, 6.00g/L of sodium chloride, 15.00g/L of mannitol, 15.00g/L of bovine serum albumin, TX-1000.3 mL/L, biological preservative PC-3002.50 mL/L, 11.00mL/L of glycerol and 3g/L of gluconic acid; the reagent 2 comprises: second antibody 0.025. mu.g/L, Tris for acridinium ester-labeled GDF15
12.11g/L, 7mL/L hydrochloric acid, 9.00g/L sodium chloride, 21.00g/L sucrose, 13.00g/L bovine serum albumin, Tween-200.5 mL/L and biological preservative PC-9503.00 mL/L.
Further, the kit for predicting or diagnosing myocarditis of the present invention further includes a calibrator. A "calibrator," a calibration material, refers to a reference material used as an independent variable in a calibration function to provide accuracy and consistency in testing and monitoring test results in vitro diagnostic clinical tests. "calibrators" may include positive calibrators (containing GDF15) and negative calibrators (not containing GDF 15).
Advantageous effects
The invention unexpectedly finds that the protein content of GDF15 in myocarditis patients is obviously higher than that of the common people, and the concentration trend of the protein content of GDF15 is the same as that of troponin T, so that GDF15 can be found as a novel marker for predicting or diagnosing myocarditis.
The invention also provides a kit for predicting or diagnosing myocarditis, and the detection object of the kit is the protein concentration of GDF15 in serum or plasma. The kit has high sensitivity, good stability, wide linear range and strong anti-interference capability, and can be widely used for clinical auxiliary diagnosis of myocarditis.
Drawings
FIG. 1 is a graph showing GDF concentration levels in different populations (normal, myocarditis).
Detailed Description
The present invention will be described in detail below with reference to specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly apparent therefrom. It will be understood by those skilled in the art that these specific embodiments and examples are for the purpose of illustrating the invention and are not to be construed as limiting the invention.
The reagent components referred to in the following examples are commercially available products, for example, magnetic particles are available from Sichuan Meeke Biotech technologies, Inc. (Cat: XCL1026), GDF15 antibody (i.e., capture antibody for coating on magnetic particles) Anti-GDF15 antibody (ab39999) from Abcam, GDF15 antibody (i.e., labeled antibody for acridinium ester labeling) from Anti-h GDF-154902SPTN-5(100658) from Medix Biochemica, Inc.
Example 1
Preparation of calibrator
First, calibrator dilutions were prepared using the compositions and ratios shown in table 1 below, and then GDF15 antigen was added to 5 calibrator dilutions to obtain calibrators a to E, respectively. Wherein the concentrations of the antigens in the calibrator A to the calibrator E are respectively as follows: CalA: 0.0 ng/mL; and (3) CalB: 0.2 ng/mL; and (3) CalC: 1 ng/mL; CalD: 5 ng/mL; and (3) CalE: 10 ng/mL.
TABLE 1 preparation of dilutions of calibrators
Name of reagent | Dilution of calibrator |
Tris | 12.11g/L |
Sodium chloride | 8.5g/L |
Hydrochloric acid | About 5-7mL/L |
Trehalose | 20.00g/L |
Bovine serum albumin | 10.00g/L |
TWeen-20 | 0.55ml/L |
Biological preservative PC-950 | 3.00mL/L |
Purified water | Constant volume is 1L |
Configuration of the kit
The kits were configured using the compositions and ratios of table 2 below.
TABLE 2 formulation of the kit
Example 2
Margin test
Using the kit prepared in example 1, the zero concentration calibrator was assayed repeatedly 20 times using a full-automatic chemiluminescence immunoassay analyzer (i3000), and the relative luminescence intensity (RLU) was recorded for 20 tests. Calculating the average value (M) and Standard Deviation (SD) of the RLU for 20 times to obtain M +2SD, substituting the value of M +2SD into the working curve of the kit (the corresponding concentration when the RLU value is M +2SD can be calculated by directly using the user software matched with the instrument), and obtaining the corresponding concentration value, namely the blank limit. The blank obtained in this example was limited to 150 pg/mL.
Detection limit and quantification limit testing
For the detection limit, the kits prepared in example 1 were used, and the calibrators a to E prepared in example 1 at 0 to 10pg/mL were each measured 10 times using a full-automatic chemiluminescence immunoassay analyzer (i3000), and after calculating the average value and Standard Deviation (SD) of the measured luminescence amount at each concentration, the lowest concentration at which the range of the measured luminescence amount average ± 3SD does not overlap the range of the luminescence amount average ± 3SD at the concentration of 0pg/mL was used as the detection limit.
For the limit of quantitation, the kits prepared in example 1 were used, and calibrators a to E prepared in example 1 at 0 to 10pg/mL were each measured 10 times using a full-automatic chemiluminescence immunoassay analyzer (i3000), and the concentration at which the CV of the measurement value calculated from the standard curve was 10% or less was defined as the limit of quantitation.
As a result, it was confirmed that GDF15 could be measured with high sensitivity, with the detection limit and the quantification limit obtained being 200pg/mL or less.
Example 3
Linear range test
A linear sample with GDF15 concentration of about 20000pg/mL was diluted with physiological saline to 9 different concentrations (dilution gradients of 0, 1/64, 1/32, 1/16, 1/8, 1/4, 1/2, 9/10, and 1, respectively) as theoretical concentrations. Each concentration was measured 3 times using the kit prepared in example 1, and the average value was calculated as the measured concentration. Calculating a linear regression equation by taking the theoretical concentration as an independent variable and the actual measurement concentration as a dependent variable, and calculating a linear regression correlation coefficient r; substituting the theoretical concentration into a linear regression equation to calculate the estimated concentration and the deviation between the measured concentration and the estimated concentration. The result shows that the linear correlation coefficient r of the kit is 1.00 and is more than 0.99; the deviation range is small, and the linear range is 300-.
Example 4
Repeatability test
An enterprise-accurate reference (i.e., two samples of GDF15 at different concentrations) was selected as the assay sample. Each sample was assayed in 10 replicates using the same batch of kits. After the measurement, the mean and standard deviation of the measurement results were calculated, respectively. And calculating the coefficient of variation of each measurement sample according to the ratio of the standard deviation to the mean value of the coefficient of variation, wherein the detection results are shown in table 3.
TABLE 3 results of repeatability tests
Enterprise precision reference product | Number of repetitions | Coefficient of variation in batch (CV) |
|
10 | 3.8 |
R2 | ||
10 | 2.7% |
As can be seen from Table 3, the kit of the invention has a variation coefficient in batch of less than 4%, and meets clinical requirements.
Intermediate precision measurement
And selecting an enterprise precision reference product as a measurement sample. Three lots of kits were taken and the assay of the samples was repeated 10 times for each lot of kits. After the measurement, the mean and standard deviation of 30 measurement results were calculated, respectively. And calculating the coefficient of variation according to the ratio of the standard deviation to the mean value of the coefficient of variation. The results are shown in Table 4.
TABLE 4 results of intermediate precision measurements
Enterprise precision reference product | Number of repetitions | Coefficient of variation between batches (CV) |
R1 | 30 | 4.2% |
R2 | 30 | 3.5% |
As can be seen from Table 4, the inter-batch coefficient of variation of the kit of the invention is less than 5%, and the requirement that the inter-batch coefficient of variation is less than 10% in clinic is met.
Example 5
Stability test
The calibrator with 5 concentration gradients in example 1 was placed in water baths at 4 ℃ and 37 ℃ for 0 day, 3 days, and 7 days, respectively, and then the kit of example 1 was used for detection, and the results are shown in table 5 below.
TABLE 5 stability test results
Calibration article | Signal retention rate (0 day) | Signal retention rate (3 days) | Signal retention rate (7 days) |
CalA | 99% | 93% | 85% |
CalB | 98% | 95% | 82% |
CalC | 96% | 94% | 83% |
CalD | 94% | 94% | 86% |
CalE | 101% | 98% | 83% |
As can be seen from Table 5, the signal retention rates of the kit of the present invention were all above 80% after being placed in a water bath at 37 ℃ for 7 days.
Example 6
Interference testing
Bilirubin solution, hemoglobin solution, triglyceride solution, biotin solution and rheumatoid factor solution of different concentration gradients were prepared from a base buffer containing the same GDF15 concentration, and the GDF concentration in the base buffer containing no interfering substance and the sample prepared above were measured using the kit of example 1 using a full-automatic chemiluminescence immunoassay analyzer (i3000), and the relative deviation between the values measured for the sample and the base buffer was calculated, and it was considered that no interference occurred within 10%.
The anti-interference result of the kit of the invention is as follows: bilirubin is less than or equal to 400 mg/dL; hemoglobin is less than or equal to 1250 mg/dL; triglyceride is less than or equal to 3400 mg/dL; biotin is less than or equal to 1000 ng/dL; the rheumatoid factor is less than or equal to 1200 IU/dL.
Example 8
Relationship of GDF15 values to myocarditis
55 myocarditis patients and 131 control groups were investigated, the control groups showing no symptoms of myocarditis and excluding the population with a known history of myocarditis disease.
Blood samples of 55 myocarditis patients and 131 control groups were tested using the kit prepared in example 1 using a full-automatic chemiluminescence immunoassay analyzer (i3000), and the GDF15 content was measured as shown in fig. 1. As can be seen from fig. 1, GDF concentration levels were not the same in different populations (normal, myocarditis patients), and it was surprisingly found that the magnitude of GDF15 was significantly higher in myocarditis patients than in the control group.
Example 9
Numerical identity of cTnI and GDF15 in patients with myocarditis
Blood samples of 40 myocarditis patients were tested using the troponin I assay kit (direct chemiluminescence method) and the kit of example 1 using a full-automatic chemiluminescence immunoassay analyzer (I3000) to obtain luminescence values as follows:
TABLE 6 detection of cTnI and GDF15 in different samples
As can be seen from the above table, although the concentrations of GDF15 and troponin I in patients with myocarditis are generally higher than those of healthy people, the numerical trends of GDF15 and troponin I in patients with different myocarditis are inconsistent, and therefore, the accuracy of predicting and/or diagnosing myocarditis can be improved by performing combined detection on cTnI and GDF 15.
Comparative example
Configuration of the contrast kit
The kits were configured using the compositions and ratios of table 7 below.
TABLE 7 formulation of comparative kits
Interference testing of contrast kits
A bilirubin solution, a hemoglobin solution, a triglyceride solution, a biotin solution and a rheumatoid factor solution having different concentration gradients were prepared from a base buffer containing the same GDF15, respectively, and the GDF concentrations in the base buffer containing no interfering substance and the sample prepared above were measured using a full-automatic chemiluminescence immunoassay analyzer (i3000) using the comparative kit of this comparative example, and the relative deviation between the values measured in the sample and the base buffer was calculated, and it was considered that no interference occurred if the deviation was within 10%.
The anti-interference result of the contrast kit is as follows: bilirubin is less than or equal to 60 mg/dL; hemoglobin is less than or equal to 1000 mg/dL; triglyceride is less than or equal to 2000 mg/dL; biotin is less than or equal to 50 ng/dL; the rheumatoid factor is less than or equal to 1200 IU/dL.
Claims (10)
1. Use of an agent for detecting the level of GDF15 concentration in serum or plasma in the manufacture of a formulation for predicting or diagnosing the risk of myocarditis in a subject.
2. The use of claim 1, wherein the subject has an increased serum or plasma concentration of GDF15, and the subject has an increased risk of developing myocarditis.
3. A kit for predicting or diagnosing myocarditis, wherein the kit is for detecting the level of GDF15 in serum or plasma.
4. The kit according to claim 3, characterized in that it further comprises a means for detecting troponin I and/or the level of troponin I concentration in serum or plasma.
5. The kit of claim 3, wherein the kit comprises:
a GDF15 first antibody conjugated to a solid support; a GDF15 second antibody labeled with a detectable label;
the first and second antibodies each specifically bind to a different epitope of GDF 15.
6. The kit of claim 3, wherein the solid support is a magnetic microparticle.
7. The kit of claim 3, wherein the detectable label is selected from the group consisting of an enzyme, biotin, digoxigenin, a colloidal metal, a fluorescent dye, and a chemiluminescent compound; preferably, the label is selected from chemiluminescent substances; preferably, the label is an acridinium ester derivative.
8. The kit of claim 3, wherein the kit comprises reagent 1 and reagent 2, wherein reagent 1 comprises: buffer, inorganic salt ions, stabilizers, surfactants, preservatives, gluconic acid, and a first antibody to magnetic microparticle coated GDF 15; the reagent 2 comprises: buffers, inorganic salt ions, stabilizers, surfactants, preservatives, and a second antibody to acridinium ester labeled GDF 15.
9. The kit according to claim 8, wherein the reagent 1 comprises: 10-200 mmol/L of buffer solution, 150-600 mmol/L of inorganic salt ions, 10-50 g/L of stabilizing agent, 0.1-1.0 mL/L of surfactant, 0.1-0.6 mL/L of preservative, 2-5 g/L of gluconic acid and 0.2-0.8 ug/mL of first antibody of GDF15 coated by magnetic particles; the reagent 2 comprises: 10-200 mmol/L of buffer solution, 150-600 mmol/L of inorganic salt ions, 10-20 g/L of stabilizing agent, 0.1-1.0 mL/L of surfactant, 0.1-0.6 mL/L of preservative and 0.05-0.4 ug/L of second antibody of acridine ester labeled GDF 15.
10. The kit of claim 3, wherein the kit comprises reagent 1 and reagent 2, wherein reagent 1 comprises: 0.5ug/mL of first antibody of GDF15 coated by magnetic particles, 2.56g/L of disodium hydrogen phosphate, 0.436g/L of sodium dihydrogen phosphate, 6.00g/L of sodium chloride, 15.00g/L of mannitol, 15.00g/L of bovine serum albumin, TX-1000.3 mL/L, biological preservative PC-3002.50 mL/L, 11.00mL/L of glycerol and 3g/L of gluconic acid; the reagent 2 comprises: 0.025 mu g/L of secondary antibody of GDF15 labeled by acridine ester, 12.11g/L of Tris, 7mL/L of hydrochloric acid, 9.00g/L of sodium chloride, 21.00g/L of sucrose, 13.00g/L of bovine serum albumin, 200.5 mL/L of Tween and 9503.00 mL/L of biological preservative PC.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110500253.5A CN113238060B (en) | 2021-05-08 | 2021-05-08 | Kit for predicting or diagnosing myocarditis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110500253.5A CN113238060B (en) | 2021-05-08 | 2021-05-08 | Kit for predicting or diagnosing myocarditis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113238060A true CN113238060A (en) | 2021-08-10 |
CN113238060B CN113238060B (en) | 2022-10-11 |
Family
ID=77132620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110500253.5A Active CN113238060B (en) | 2021-05-08 | 2021-05-08 | Kit for predicting or diagnosing myocarditis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113238060B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113552372A (en) * | 2021-09-18 | 2021-10-26 | 湖南永和阳光生物科技股份有限公司 | Magnetic particle chemiluminescence immunoassay kit for SAA detection and preparation method thereof |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1215168A (en) * | 1997-10-17 | 1999-04-28 | 库特国际公司 | Cyanide-free reagent and method for hemoglobin determination and leukocyte differentiation |
WO2003099320A1 (en) * | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
CN1967252A (en) * | 2006-10-30 | 2007-05-23 | 宁波美康生物科技有限公司 | Direct bilirubin detecting kit |
WO2008093323A2 (en) * | 2007-01-29 | 2008-08-07 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
AU2008251822A1 (en) * | 2007-05-10 | 2008-11-20 | Acorda Therapeutics, Inc. | Methods for detecting cardiac damage |
US20090304680A1 (en) * | 2008-05-09 | 2009-12-10 | Agency For Science, Technology And Research (A*Star) | Diagnosis and treatment of kawasaki disease |
CN101999002A (en) * | 2008-02-04 | 2011-03-30 | 彼帕科学公司 | Methods of diagnosing and treating PARP-mediated diseases |
CN201796035U (en) * | 2010-07-01 | 2011-04-13 | 四川迈克生物科技股份有限公司 | Kit for rapid detection of mycobacterium tuberculosis antibody |
CN102741423A (en) * | 2009-10-23 | 2012-10-17 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
CN103237901A (en) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarkers for theranostics |
US20140175018A1 (en) * | 2011-06-13 | 2014-06-26 | Ith Immune Therapy Holdings Ab | Diagnosing and Treating Inflammatory Diseases |
CN104535560A (en) * | 2015-01-13 | 2015-04-22 | 同昕生物技术(北京)有限公司 | Enzymatic chemiluminescent substrate liquid |
EP2896964A1 (en) * | 2014-01-16 | 2015-07-22 | Ernst-Moritz-Arndt-Universität Greifswald | MD-2 as biomarker in heart failure |
CN105388146A (en) * | 2015-10-20 | 2016-03-09 | 北京中生金域诊断技术股份有限公司 | Kit for simultaneously detecting sodium, creatinine and microalbumin in urine |
US20160356789A1 (en) * | 2015-04-06 | 2016-12-08 | True Health Diagnostics Llc | Method of Detection of Summed Cardiac Troponins for Cardiovascular Risk Stratification |
CN106232623A (en) * | 2014-04-22 | 2016-12-14 | Txp制药股份有限公司 | There is the peptide analogues of branched-amino acid probe |
CN106443014A (en) * | 2016-09-20 | 2017-02-22 | 上海科华生物工程股份有限公司 | Detection kit for ischemia modified albumin and preparation method of detection kit |
CN106596981A (en) * | 2016-12-09 | 2017-04-26 | 青岛古高生物科技有限公司 | Kit for determining blood coagulation function |
US20170233798A1 (en) * | 2010-10-22 | 2017-08-17 | T2 Biosystems, Inc. | Nmr systems and methods for the rapid detection of analytes |
WO2017188403A1 (en) * | 2016-04-27 | 2017-11-02 | ロート製薬株式会社 | Mesenchymal stem cell expressing at least one cell surface marker selected from the group consisting of cd201, cd46, cd56, cd147, and cd165 and method for preparing same, and pharmaceutical composition containing the mesenchymal stem cell and method for preparing same |
CN107422129A (en) * | 2017-01-15 | 2017-12-01 | 北京科跃中楷生物技术有限公司 | A kind of super quick cardiac muscle troponin I magnetic microsphere immunoturbidimetry detection method and detection kit |
CN108593936A (en) * | 2011-06-29 | 2018-09-28 | 塞尔雷斯蒂斯有限公司 | Cell-mediated immune response with enhancing sensitivity measures |
US20190002977A1 (en) * | 2015-12-23 | 2019-01-03 | Sanofi-Aventis Deutschland Gmbh | Growth Differentiation Factor 15 as Biomarker for Metformin |
CN109406796A (en) * | 2018-12-11 | 2019-03-01 | 迈克生物股份有限公司 | Rheumatoid factor detection reagent box and its detection method |
US20190374600A1 (en) * | 2015-09-17 | 2019-12-12 | Histide Ag | Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
CN111273042A (en) * | 2020-01-21 | 2020-06-12 | 迈克生物股份有限公司 | Anti mullerian tube hormone detect reagent box |
CN111381050A (en) * | 2020-04-21 | 2020-07-07 | 南通大学 | Experimental method for Reg3 β/HMGB1 loop to regulate reprogramming of EAM mouse macrophages |
CN111712260A (en) * | 2018-01-31 | 2020-09-25 | 伊夫罗生物科学公司 | Compositions and methods for treating immune disorders using bacteria of the family lachnospiraceae |
CN112698041A (en) * | 2020-12-16 | 2021-04-23 | 深圳上泰生物工程有限公司 | Compound, growth differentiation factor 15 detection kit thereof and application |
-
2021
- 2021-05-08 CN CN202110500253.5A patent/CN113238060B/en active Active
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1215168A (en) * | 1997-10-17 | 1999-04-28 | 库特国际公司 | Cyanide-free reagent and method for hemoglobin determination and leukocyte differentiation |
WO2003099320A1 (en) * | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
CN1967252A (en) * | 2006-10-30 | 2007-05-23 | 宁波美康生物科技有限公司 | Direct bilirubin detecting kit |
WO2008093323A2 (en) * | 2007-01-29 | 2008-08-07 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
AU2008251822A1 (en) * | 2007-05-10 | 2008-11-20 | Acorda Therapeutics, Inc. | Methods for detecting cardiac damage |
CN101999002A (en) * | 2008-02-04 | 2011-03-30 | 彼帕科学公司 | Methods of diagnosing and treating PARP-mediated diseases |
US20090304680A1 (en) * | 2008-05-09 | 2009-12-10 | Agency For Science, Technology And Research (A*Star) | Diagnosis and treatment of kawasaki disease |
CN102741423A (en) * | 2009-10-23 | 2012-10-17 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
CN103237901A (en) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarkers for theranostics |
CN201796035U (en) * | 2010-07-01 | 2011-04-13 | 四川迈克生物科技股份有限公司 | Kit for rapid detection of mycobacterium tuberculosis antibody |
US20170233798A1 (en) * | 2010-10-22 | 2017-08-17 | T2 Biosystems, Inc. | Nmr systems and methods for the rapid detection of analytes |
US20140175018A1 (en) * | 2011-06-13 | 2014-06-26 | Ith Immune Therapy Holdings Ab | Diagnosing and Treating Inflammatory Diseases |
CN108593936A (en) * | 2011-06-29 | 2018-09-28 | 塞尔雷斯蒂斯有限公司 | Cell-mediated immune response with enhancing sensitivity measures |
EP2896964A1 (en) * | 2014-01-16 | 2015-07-22 | Ernst-Moritz-Arndt-Universität Greifswald | MD-2 as biomarker in heart failure |
CN106232623A (en) * | 2014-04-22 | 2016-12-14 | Txp制药股份有限公司 | There is the peptide analogues of branched-amino acid probe |
CN104535560A (en) * | 2015-01-13 | 2015-04-22 | 同昕生物技术(北京)有限公司 | Enzymatic chemiluminescent substrate liquid |
US20160356789A1 (en) * | 2015-04-06 | 2016-12-08 | True Health Diagnostics Llc | Method of Detection of Summed Cardiac Troponins for Cardiovascular Risk Stratification |
US20190374600A1 (en) * | 2015-09-17 | 2019-12-12 | Histide Ag | Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
CN105388146A (en) * | 2015-10-20 | 2016-03-09 | 北京中生金域诊断技术股份有限公司 | Kit for simultaneously detecting sodium, creatinine and microalbumin in urine |
US20190002977A1 (en) * | 2015-12-23 | 2019-01-03 | Sanofi-Aventis Deutschland Gmbh | Growth Differentiation Factor 15 as Biomarker for Metformin |
WO2017188403A1 (en) * | 2016-04-27 | 2017-11-02 | ロート製薬株式会社 | Mesenchymal stem cell expressing at least one cell surface marker selected from the group consisting of cd201, cd46, cd56, cd147, and cd165 and method for preparing same, and pharmaceutical composition containing the mesenchymal stem cell and method for preparing same |
CN106443014A (en) * | 2016-09-20 | 2017-02-22 | 上海科华生物工程股份有限公司 | Detection kit for ischemia modified albumin and preparation method of detection kit |
CN106596981A (en) * | 2016-12-09 | 2017-04-26 | 青岛古高生物科技有限公司 | Kit for determining blood coagulation function |
CN107422129A (en) * | 2017-01-15 | 2017-12-01 | 北京科跃中楷生物技术有限公司 | A kind of super quick cardiac muscle troponin I magnetic microsphere immunoturbidimetry detection method and detection kit |
CN111712260A (en) * | 2018-01-31 | 2020-09-25 | 伊夫罗生物科学公司 | Compositions and methods for treating immune disorders using bacteria of the family lachnospiraceae |
CN109406796A (en) * | 2018-12-11 | 2019-03-01 | 迈克生物股份有限公司 | Rheumatoid factor detection reagent box and its detection method |
CN111273042A (en) * | 2020-01-21 | 2020-06-12 | 迈克生物股份有限公司 | Anti mullerian tube hormone detect reagent box |
CN111381050A (en) * | 2020-04-21 | 2020-07-07 | 南通大学 | Experimental method for Reg3 β/HMGB1 loop to regulate reprogramming of EAM mouse macrophages |
CN112698041A (en) * | 2020-12-16 | 2021-04-23 | 深圳上泰生物工程有限公司 | Compound, growth differentiation factor 15 detection kit thereof and application |
Non-Patent Citations (7)
Title |
---|
DEVIN W.KEHL 等: "Biomarkers in acute myocardial injury", 《TRANSLATIONAL RESEARCH》 * |
SHINSUKE HOSHINO 等: "Biomarkers of Inflammation and Fibrosis in Kawasaki Disease Patients Years After Initial Presentation With Low Ejection Fraction", 《JOURNAL OF THE AMERICAN HEART ASSOCIATION》 * |
叶伟平 等: "儿童心肌损伤生物标志物的应用和研究进展", 《浙江医学》 * |
周秀 等: "血清生长分化因子15、和肽素、缺血修饰清蛋白浓度对急性冠脉综合征患者PCI治疗后心肌损伤的预测价值", 《岭南心血管病杂志》 * |
张汉卿: "新型口服抗凝药在急性缺血性脑卒中的应用", 《中国卫生标准管理》 * |
徐莹莹 等: "轮状病毒肠炎致心肌损伤患儿血清GDF-15、hs-CRP水平及临床意义的研究", 《中国妇幼保健》 * |
高凤敏 等: "急诊介入治疗对急性心肌梗死病人血清炎性因子的影响及临床意义", 《中西医结合心脑血管病杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113552372A (en) * | 2021-09-18 | 2021-10-26 | 湖南永和阳光生物科技股份有限公司 | Magnetic particle chemiluminescence immunoassay kit for SAA detection and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113238060B (en) | 2022-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11959912B2 (en) | Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof | |
US10472400B2 (en) | Cardiac troponin I ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor | |
CN109917134B (en) | Calibrator stabilizer, detection kit for determining C peptide and detection method | |
CN114034872A (en) | Kit for early diagnosis of Alzheimer's disease and application thereof | |
Brandt et al. | Quantifying the MB isoenzyme of creatine kinase with the Abbott" IMx" immunoassay analyzer | |
CN113238060B (en) | Kit for predicting or diagnosing myocarditis | |
CN106366199B (en) | Troponin I monoclonal antibody magnetic particle, preparation method thereof and detection kit | |
JP2972353B2 (en) | Reagents that improve annexin recovery | |
CN116047087B (en) | Method for judging free biotin in sample | |
CN112305228B (en) | Myoglobin direct chemiluminescence detection kit, preparation method and application | |
CN116298311A (en) | Magnetic particle chemiluminescence kit for quantitatively detecting interleukin 18 and application thereof | |
CN113238055A (en) | Kit for detecting procalcitonin by using space proximity chemiluminescence method, and detection method and application thereof | |
CN112129933B (en) | Reagent, kit and method for resisting biological interference in immunoassay system | |
CN111175515B (en) | Two-in-one quality control substance of serum amyloid A and serum amyloid C reactive protein and preparation method thereof | |
CN115656153B (en) | Anti-nuclear antibody spectrum detection kit based on acridinium ester chemiluminescence | |
CN106645744A (en) | Homogeneous fluorescence immunoassay reagent for rapid and quantitative detection of troponin T and preparation and detection methods thereof | |
Tang et al. | Establishment of a micro-spheres-based homogeneous fluorescence immunoassay for the rapid detection of cardiac troponin I | |
Boerman et al. | Time-resolved immunofluorometric assay for the ovarian carcinoma-associated antigenic determinant CA 125 in serum. | |
CN113933497A (en) | I type collagen amino-terminal extension peptide magnetic particle chemiluminescence immunoassay kit and detection method thereof | |
US20230113252A1 (en) | Method of determining development of myocarditis or risk of myocarditis development | |
CN116519945A (en) | Magnetic particle chemiluminescence detection kit for rapidly determining content of soluble ST2 | |
CN118191338A (en) | Chemiluminescent immunoassay kit for detecting heat shock protein 70 and preparation method and application thereof | |
CN113238063A (en) | Use of GDF15 to assess the progression of metabolic syndrome patients to cardiovascular disease | |
CN114578054A (en) | Kit for quantitative combined detection of cytokines | |
CN115656153A (en) | Antinuclear antibody spectrum detection kit based on acridinium ester chemiluminescence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |